title: Humoral hypercalcemia caused by uterine corpus carcinosarcoma consisting of squamous cell carcinoma in its epithelial component.
abstract: Humoral hypercalcemia of malignancy (HHM) is a paraneoplastic syndrome primarily caused by a tumor-producing parathyroid hormone-related protein (PTH-rP). We describe the first reported case of a uterine carcinosarcoma causing HHM. A 70-year-old patient was transferred to our hospital for a uterine tumor accompanied by impaired consciousness. The laboratory tests indicated anemia, malnutrition, elevated serum calcium and elevated PTH-rP. Emergency surgery, including abdominal hysterectomy and bilateral salpingo-oophorectomy, was performed due to uncontrollable uterine bleeding. The pathological diagnosis was carcinosarcoma consisting of pure squamous cell carcinoma in its epithelial component. Postoperatively, chemotherapy with paclitaxel and carboplatin was performed. The patient had recurrent tumors at the para-aortic lymph nodes 11 months after the initial surgery and underwent a pelvic and para-aortic lymphadenectomy, which removed all of the recurrent tumors.
authors.affiliation: Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: Shiro
authors.initials: S
authors.lastname: Takamatsu
authors.forename: Noriomi
authors.initials: N
authors.lastname: Matsumura
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Baba
authors.forename: Masaki
authors.initials: M
authors.lastname: Mandai
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Mikami
authors.forename: Ikuo
authors.initials: I
authors.lastname: Konishi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery; D002296:Carcinosarcoma / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004717:Endometrium / Q000473:pathology*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology* / Q000517:prevention & control; D007044:Hysterectomy; D010052:Ovariectomy; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D010257:Paraneoplastic Syndromes / Q000209:etiology* / Q000517:prevention & control; D058994:Salpingectomy; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000209:etiology / Q000517:prevention & control; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery; D014599:Uterus / Q000473:pathology* / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D017239:Paclitaxel
keywords: carcinosarcoma; hypercalcemia; parathyroid hormone-related protein; squamous cell carcinoma; uterine neoplasms